NO20090164L - Combination preparations including SLV308 and an L-DOPA - Google Patents

Combination preparations including SLV308 and an L-DOPA

Info

Publication number
NO20090164L
NO20090164L NO20090164A NO20090164A NO20090164L NO 20090164 L NO20090164 L NO 20090164L NO 20090164 A NO20090164 A NO 20090164A NO 20090164 A NO20090164 A NO 20090164A NO 20090164 L NO20090164 L NO 20090164L
Authority
NO
Norway
Prior art keywords
slv308
dopa
preparations including
combination preparations
simultaneous
Prior art date
Application number
NO20090164A
Other languages
Norwegian (no)
Inventor
Gustaaf Johan Marie Van Scharrenburg
Martinus Th M Tulp
Andrew C Mccreary
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20090164L publication Critical patent/NO20090164L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår anvendelsen av et kombinasjonspreparat av SLV308 eller dets N-oksid, eller farmakologisk akseptable salter av disse forbindelsene (I), (II) og L-DOPA, for samtidig, separat eller sekvensiell anvendelse i behandlingen av lidelser som krever gjenvinning av dopaminergisk funksjon, spesielt Parkinsons sykdom og rastløse ben syndrom.The invention relates to the use of a combination preparation of SLV308 or its N-oxide, or pharmacologically acceptable salts of these compounds (I), (II) and L-DOPA, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function. , especially Parkinson's disease and restless leg syndrome.

NO20090164A 2006-06-16 2009-01-12 Combination preparations including SLV308 and an L-DOPA NO20090164L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405106P 2006-06-16 2006-06-16
EP06115583 2006-06-16
PCT/EP2007/055955 WO2007144421A1 (en) 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a l-dopa

Publications (1)

Publication Number Publication Date
NO20090164L true NO20090164L (en) 2009-01-14

Family

ID=38434785

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090164A NO20090164L (en) 2006-06-16 2009-01-12 Combination preparations including SLV308 and an L-DOPA

Country Status (10)

Country Link
EP (1) EP2035002A1 (en)
JP (1) JP2009539941A (en)
KR (1) KR20090031908A (en)
AU (1) AU2007259255A1 (en)
CA (1) CA2654719A1 (en)
EA (1) EA015073B1 (en)
IL (1) IL195532A0 (en)
MY (1) MY148457A (en)
NO (1) NO20090164L (en)
WO (1) WO2007144421A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7596407B2 (en) * 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
KR20070059161A (en) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
RU2394821C2 (en) * 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-oxides as prodrug of piperazine and piperidine derivatives

Also Published As

Publication number Publication date
EA015073B1 (en) 2011-04-29
CA2654719A1 (en) 2007-12-21
MY148457A (en) 2013-04-30
WO2007144421A1 (en) 2007-12-21
JP2009539941A (en) 2009-11-19
KR20090031908A (en) 2009-03-30
AU2007259255A1 (en) 2007-12-21
EP2035002A1 (en) 2009-03-18
IL195532A0 (en) 2009-09-01
EA200970021A1 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
MX2009011359A (en) Pyrimidinone derivatives and methods of use thereof.
NO20081592L (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
JO2756B1 (en) 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
NO20082768L (en) Levodopa prodrug mesylate, compositions and uses thereof
NO20084752L (en) Conjugates of aziridinayl epothilone analogs and pharmaceutical compositions containing them
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010006204A (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases.
MX2009009416A (en) Benzimidazole derivatives and methods of use thereof.
MX2020008616A (en) Sublingual fentanyl spray.
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
NO20090165L (en) Combination preparations including bifeprunox and L-DOPA
NO20085257L (en) Purinone derivatives as HM74a agonists
NO20085099L (en) Puriton derivatives such as HM74A agonists
DK2013166T3 (en) N-carbamoylmethyl-4 (R) -phenyl-2-pyrrolidone, process for its preparation and pharmaceutical use
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
UA92730C2 (en) Benzazole analogues and use thereof
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
DK2175877T3 (en) Use of mutated antithrombin for the treatment or prevention of coagulation disorders
NO20090164L (en) Combination preparations including SLV308 and an L-DOPA
WO2007144699A3 (en) Process for the preparation of alfuzosin
CY1116166T1 (en) NEW METHOD FOR TREATMENT OF H.PYLORI INFECTIONS
MX2012001107A (en) Amide derivative.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application